Previous 10 | Next 10 |
Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier. Viatris' generic and brand drug sales have been declining year on yea...
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
Women’s health company Organon (NYSE:OGN) announced on Monday an agreement with Chinese biopharmaceutical company Shanghai Henlius Biotech, Inc. (OTCPK:SGBCF) for commercialization of two biosimilar candidates targeted at conditions such as breast cancer and osteoporosis. Pertuzumab is...
Collaboration expands and underscores commitment to biosimilars portfolio and focus on women’s health with biosimilar candidates for osteoporosis and breast cancer Organon (NYSE: OGN), a global women’s health company with deep expertise in biosimilar commercial...
BofA Securities is out with a list of stocks that should benefit from a transforming world. "The changing composition of the global population in the decades to come will be transformational," BofA analysts wrote in a note. "The global population has doubled in the past 50 years, but declinin...
The U.S. Food and Drug Administration (FDA) has for the first time required labeling changes to the popular anti-baldness pill Propecia marketed by Organon (NYSE:OGN) to reflect the risk of suicidal behavior in men taking the drug. Previously, the FDA has required labeling changes to the medi...
On One Year Anniversary, Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report Canada NewsWire Report lays out blueprint for achieving Organon's purpose and business imperatives to help wo...
Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health Launch of Her Promise ESG platform creates a framework by which the company will advance innovation and progress in w...
Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks dipped into bear market territory on Friday, with the S&P 500's decline from its January all-time high hitting 20% at one point, before a late-s...
Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...